Procter & Gamble Health Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Procter & Gamble Health Limited reported unaudited results for Q1 FY2026 (quarter ended June 30, 2025). Revenue from operations rose 19.3% year-on-year to ₹33,874 lakhs, up from ₹28,388 lakhs in Q1 FY2025. Net profit jumped to ₹6,618 lakhs from ₹1,678 lakhs, though the prior-year figure was weighed down by a one-time exceptional charge of ₹2,019 lakhs tied to the discontinuation and sale of the Goa injection plant. On a like-for-like (pre-exceptional) basis, profit before tax also grew sharply from ₹4,302 lakhs to ₹8,881 lakhs, indicating strong underlying growth. Basic and diluted EPS for the quarter stood at ₹39.87 versus ₹10.11 a year ago. Statutory auditor Haribhakti & Co. LLP issued an unmodified limited review report. The company also noted that FY 2024-25 was a transitional 9-month period following the shift in financial year-end from June 30 to March 31.
The headline profit surge is partly flattered by a low base from prior-year exceptional costs, but underlying operating performance shows robust top-line growth and significant margin expansion — a positive signal for shareholders and likely supportive of the stock.